Physician profile
Timothy J Bright
NPI 1760405393
$1,302.09
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,078 · 2020: $224.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $305.85 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $197.05 | 2019 | |
| Novo Nordisk INC | $164.43 | 2019 | |
| Avanir Pharmaceuticals, INC. | $135.22 | 2019 | |
| Allergan, INC. | $120.48 | 2020 | |
| Amgen INC. | $63.40 | 2019-2020 | |
| Astellas Pharma US INC | $61.88 | 2019 | |
| Amarin Pharma, INC. | $56.49 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.73 | 2019 | |
| Lilly USA, LLC | $35.69 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.89 | 2019 | |
| Supernus Pharmaceuticals, INC. | $22.45 | 2019 | |
| Genentech USA, INC. | $21.34 | 2019 | |
| Glaxosmithkline, LLC. | $15.85 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.34 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Bright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.